Jordan Berlin, MD
Medical Oncology · Nashville, TNNPI 1275620312
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $88,090 of the $119,787 with a category attached, or 73.5%. 18 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 24.4% of the total. 2025 is the largest year on record at $40,244, 2.5 times the $15,990 reported in 2019.
Across 89 payments — averaging $1345.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$29K
- Merck Healthcare Kgaa$16K
- Bayer$13K
- EMD Serono Research & Development Institute, Inc.$10K
- EMD Serono, Inc.$8K
- Taiho Oncology, Inc.$7K
- plus $36K from 12 others
Across 1,028 payments — averaging $3508.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Inc$1.1M
- Incyte Corporation$723K
- AbbVie$350K
- E.r. Squibb & Sons, L.L.C.$241K
- Pfizer$232K
- EMD Serono, Inc.$210K
- plus $740K from 16 others
What the payments were for
- Consulting fees$88,09074%
- Speaking & faculty fees$12,83811%
- Travel & lodging$15,68613%
- Food & beverage$1,5141%
- Education$1,6591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 25 | $29,218 |
| Merck Healthcare Kgaa | 4 | $16,004 |
| Bayer | 7 | $12,950 |
| EMD Serono Research & Development Institute, Inc. | 2 | $9,750 |
| EMD Serono, Inc. | 10 | $8,307 |
| Taiho Oncology, Inc. | 7 | $7,196 |
| Novocure Inc. | 7 | $6,921 |
| Insmed, Inc. | 1 | $5,950 |
| Astrazeneca UK Limited | 4 | $4,864 |
| Regeneron | 5 | $4,473 |
| Boehringer Ingelheim International GmbH | 2 | $4,250 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,249 |
| Beigene USA, Inc. | 2 | $1,650 |
| Mirati Therapeutics, Inc. | 3 | $1,560 |
| Clovis Oncology, Inc. | 2 | $1,554 |
| Bristol Myers Squibb | 3 | $698 |
| Exelixis Inc. | 1 | $125 |
| Karyopharm Therapeutics Inc. | 1 | $69 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$119,787 in reported general payments places this provider in the 85th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Nashville
- William PaoNashville$838K
- Dana ThompsonNashville$339K
- Robert RamirezNashville$321K
- Mace RothenbergNashville$318K
- Melissa JohnsonNashville$290K
- Cathy EngNashville$231K
- David SpigelNashville$167K
- Michael GibsonNashville$141K
- Vandana AbramsonNashville$98K
- Leora HornNashville$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.